Glucaric acid

Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Glucaric acid?

Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Glucaric acid

MeSH term MeSH ID Detail
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adenoma D000236 40 associated lipids
Alcoholism D000437 27 associated lipids
Anemia D000740 21 associated lipids
Anemia, Neonatal D000751 1 associated lipids
Anemia, Refractory D000753 3 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Ascorbic Acid Deficiency D001206 9 associated lipids
Biliary Tract Diseases D001660 3 associated lipids
Body Weight D001835 333 associated lipids
Calcium Metabolism Disorders D002128 1 associated lipids
Carbon Tetrachloride Poisoning D002252 12 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Brain Ischemia D002545 89 associated lipids
Dehydration D003681 11 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Edema D004487 152 associated lipids
Epilepsy D004827 35 associated lipids
Per page 10 20 50 100 | Total 85

PubChem Associated disorders and diseases

What pathways are associated with Glucaric acid

Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Glucaric acid?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Glucaric acid?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Glucaric acid?

There are no associated biomedical information in the current reference collection.

What genes are associated with Glucaric acid?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Glucaric acid?

Knock-out

Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Glucaric acid

Download all related citations
Per page 10 20 50 100 | Total 1061
Authors Title Published Journal PubMed Link
Kriebel D et al. Detection of occupational exposure to genotoxic agents with a urinary mutagen assay. 1983 Mutat. Res. pmid:6835232
Scassellati-Sforzolini G et al. In vivo studies on genotoxicity of pure and commercial linuron. 1997 Mutat. Res. pmid:9186570
Auerbach M and Rodgers GM Intravenous iron. 2007 N. Engl. J. Med. pmid:17611217
McLean AE Cancer and nutrition (review). 1976 Nahrung pmid:781541
Gomollón F and Gisbert JP IBD: Intravenous iron in IBD--what's the best preparation? 2011 Nat Rev Gastroenterol Hepatol pmid:21788975
Dueber JE et al. Synthetic protein scaffolds provide modular control over metabolic flux. 2009 Nat. Biotechnol. pmid:19648908
DeLisa MP and Conrado RJ Synthetic metabolic pipelines. 2009 Nat. Biotechnol. pmid:19668178
Faber F et al. Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion. 2016 Nature pmid:27309805
Fernández-Gallego J et al. [Treatment with intravenous iron and ferritin level]. 2010 Nefrologia pmid:20514109
Balázová E et al. Antitumor activity of four polymer bound trans-1,2-diaminocyclohexaneplatinum(II)-4-carboxyphtalate complexes tested in different model systems. 1986 Neoplasma pmid:3808121
Hrubisko M et al. Drug resistance induction and cross-resistance studies with Pt-complexes. 1984 Neoplasma pmid:6542968
Edwards JH Clinical review of the newer intravenous iron therapy options. 2003 Nephrol Nurs J pmid:12674953
Folkert VW Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients. 2003 Nephrol Nurs J pmid:14621635
Colfer M Achieving optimal patient outcomes with intravenous iron. 2003 Nephrol Nurs J pmid:14533524
Stoves J et al. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. 2001 Nephrol. Dial. Transplant. pmid:11328902
Carlini RG et al. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. 2006 Nephrol. Dial. Transplant. pmid:16957011
Schiesser D et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. 2006 Nephrol. Dial. Transplant. pmid:16891647
Guz G et al. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. 2006 Nephrol. Dial. Transplant. pmid:16762960
Chuang CL et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. 2003 Nephrol. Dial. Transplant. pmid:12543894
Parkkinen J et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. 2000 Nephrol. Dial. Transplant. pmid:11071973
Fell LH et al. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. 2016 Nephrol. Dial. Transplant. pmid:27190361
Silverberg D et al. The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure. 2004 Nephrol. Dial. Transplant. pmid:15031380
Airy M et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. 2015 Nephrol. Dial. Transplant. pmid:26311216
Bhandari S et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. 2015 Nephrol. Dial. Transplant. pmid:25925701
Onken JE et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. 2014 Nephrol. Dial. Transplant. pmid:23963731
McMahon LP et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. 2010 Nephrol. Dial. Transplant. pmid:19906658
Rottembourg J et al. Do two intravenous iron sucrose preparations have the same efficacy? 2011 Nephrol. Dial. Transplant. pmid:21355067
Wang S et al. Chemical reactions of vitamin C with intravenous-iron formulations. 2008 Nephrol. Dial. Transplant. pmid:17951305
al-Hawas F et al. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. 1997 Nephrol. Dial. Transplant. pmid:9430909
Sunder-Plassmann G and Hörl WH Safety of intravenous injection of iron saccharate in haemodialysis patients. 1996 Nephrol. Dial. Transplant. pmid:8918625
George P et al. Coronary artery vasospasm with iron sucrose. 2007 Nephrol. Dial. Transplant. pmid:17327282
Sunder-Plassmann G et al. The dilemma of evaluating iron status in dialysis patients--limitations of available diagnostic procedures. 1997 Nephrol. Dial. Transplant. pmid:9269632
Lim PS et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. 1999 Nephrol. Dial. Transplant. pmid:10534512
Ranfaing E [Treatments of the martial deficiencies: preparations available in France]. 2006 Nephrol. Ther. pmid:17373280
Tiranathanagul K et al. Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients. 2004 Nephrology (Carlton) pmid:15363053
Wu CJ et al. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients. 2010 Nephrology (Carlton) pmid:20377770
Garcia-Fernandez N et al. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. 2010 Nephrology (Carlton) pmid:20470276
Ozdemir A et al. Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. 2005 Nephrology (Carlton) pmid:16221090
Descombes E and Fellay G Improved response to erythropoietin therapy with long-term continuous iron supplementation. 2000 Nephron pmid:10657727
Silverberg DS et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. 1996 Nephron pmid:8852489
Sheashaa H et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. 2005 Nephron Clin Pract pmid:15692217
Stefánsson BV et al. Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. 2011 Nephron Clin Pract pmid:21196770
Charytan C et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. 2004 Nephron Clin Pract pmid:14988600
Frezza M et al. Abnormal serum gamma-glutamyltranspeptidase in alcoholics. Clues to its explanation. 1989 Neth J Med pmid:2563572
Ciuffi M et al. Lipid peroxidation induced "in vivo" by iron-carbohydrate complex in the rat brain cortex. 1991 Neurochem. Res. pmid:2052138
Koller WC et al. Metabolism of glucurolactone to glucarate in Parkinson's disease. 1992 Neurology pmid:1513472
de Wolff FA et al. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate. 1982 Neuropediatrics pmid:6123089
Masaki H [Metabolic pathway of D-glucaric acid synthesis from D-glucuronolactone in the skin. II. Identification of the intermediates in D-glucuronolactone D-glucaric acid metabolism]. 1972 Nihon Hifuka Gakkai Zasshi pmid:4540858
Nasaki H [Metabolic pathway of D-glucaric acid synthesis from D-glucuronolactone in the skin. 1. D-glucaric acid and D-glucuronolactone dehydrogenase activities in the human skin--feedback mechanism of beta-glucuronidase]. 1972 Nihon Hifuka Gakkai Zasshi pmid:4540880
Ogi M et al. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients]. 2004 Nihon Jinzo Gakkai Shi pmid:15645737